Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2b, Randomized, Double Blind, Placebo Controlled Active Comparator, Multicenter Study To Compare 5 Dose Regimens Of CP- 690,550 And Adalimumab Versus Placebo, Administered For 6 Months In The Treatment Of Subjects With Active Rheumatoid Arthritis
Brief Summary: The purpose of this study is to determine the effectiveness and safety, over 6 months, of 5 doses of CP-690,550 for the treatment of adults with active rheumatoid arthritis. Five out of seven subjects will receive CP-690,550. One out of seven will receive adalimumab (Humira®) and one out of seven will only receive inactive substances (placebo.)


Options:
A: Arm Label: DB Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Double-blind Placebo | Arm Label: DB adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Double-blind adalimumab | Arm Label: DB Adalimumab/OL Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Double-blind adalimumab, Biological: Open-label Adalimumab | Arm Label: DB Placebo/OL Adalimumab; Type: EXPERIMENTAL; Interventions: Drug: Double-blind Placebo, Biological: Open-label Adalimumab | Arm Label: DB Adalimumab/RE OL Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Double-blind adalimumab, Biological: Open-label Adalimumab, Biological: Open-labelAdalimumabRescue | Arm Label: DB Placebo/RE OL Adalimumab; Type: EXPERIMENTAL; Interventions: Drug: Double-blind Placebo, Biological: Open-label Adalimumab, Biological: Open-labelAdalimumabRescue | Intervention Type: BIOLOGICAL; Name: Double-blind adalimumab; Assigned to Arm(s): DB Adalimumab/OL Adalimumab, DB Adalimumab/RE OL Adalimumab, DB adalimumab | Intervention Type: DRUG; Name: Double-blind Placebo; Assigned to Arm(s): DB Placebo, DB Placebo/OL Adalimumab, DB Placebo/RE OL Adalimumab | Intervention Type: BIOLOGICAL; Name: Open-label Adalimumab; Assigned to Arm(s): DB Adalimumab/OL Adalimumab, DB Adalimumab/RE OL Adalimumab, DB Placebo/OL Adalimumab, DB Placebo/RE OL Adalimumab | Intervention Type: BIOLOGICAL; Name: Open-labelAdalimumabRescue; Assigned to Arm(s): DB Adalimumab/RE OL Adalimumab, DB Placebo/RE OL Adalimumab
B: N/A
C: Arm Label: Open Label Infliximab + Methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Infliximab + methotrexate (MTX) | Intervention Type: BIOLOGICAL; Name: Infliximab + methotrexate (MTX); Assigned to Arm(s): Open Label Infliximab + Methotrexate
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690-550 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: CP-690-550 | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: CP-690-550 | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 6; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 7; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: CP-690-550; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: CP-690-550; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: CP-690-550; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 7

Answer: D